Therapeutic developments in acute lymphoblastic leukemia

References

• Faderl S, O’Brien S, Pui C, et al. Adult acute lymphoblastic leukemia – concepts and strategies. Cancer. 116(5):1165–1176, 2010.
   PubMed Web of Science ®Google Scholar
• Armstrong SA, Look AT Molecular Genetics of Acute Lymphoblastic Leukemia. J Clin Oncol. 2005;23:6306–6315.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV Downing JR Mechanisms of Disease: Acute Lymphoblastic Leukemia. N Engl J Med. 2004;350:1535–1548.
   PubMed Web of Science ®Google Scholar
• Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet. 2008;371(9617):1030–1043.
   PubMed Web of Science ®Google Scholar
• Pui CH, Relling MV Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004;350(15):1535–1548.
   PubMed Web of Science ®Google Scholar
• Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354(2):166–178.
   PubMed Web of Science ®Google Scholar
• Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532–543.
   PubMed Web of Science ®Google Scholar
• American Cancer Society. Leukemia: acute lymphocytic (adults). Atlanta, GA: American Cancer Society; 2012 [updated January 23, 2012]. Available from: http://www.cancer.org/Cancer/Leukemia-AcuteLymphocyti- cALLinAdults/DetailedGuide/index. Access date December 2011.
   Google Scholar
• Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98(7):1337–1354.
   PubMed Web of Science ®Google Scholar
• Gale KB, Ford AM, Repp R, et al. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc Natl Acad Sci U S A. 1997;94(25):13950–13954.
   Web of Science ®Google Scholar
• Moorman AV Chilton L, Wilkinson J, Ensor HM, Bown N, Proctor SJ. A population-based cytogenetic study of adults with acute lymphoblastic leukemia. Blood. 2010;115(2):206–214.
   PubMed Web of Science ®Google Scholar
• Pullarkat V Slovak ML, Kopecky KJ, Forman SJ, Appelbaum FR. Impact of cytogenetics on the outcome of adult acute lymphoblastic leukemia: results of Southwest Oncology Group 9400 study. Blood. 2008;111(5):2563–2572.
   PubMed Web of Science ®Google Scholar
• Schnapp LM. Another notch on the belt. Blood. 2008;113(8):1615–1616.
   Web of Science ®Google Scholar
• Palomero TL, Lim WK, Odom DT, et al. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A. 2006;103(48):18261–18266.
   PubMed Web of Science ®Google Scholar
• Armstrong SA, Look AT. Molecular genetics of acute lymphoblastic leukemia. J Clin Oncol. 2005;23(26):6306–6315.
   PubMed Web of Science ®Google Scholar
• Mullighan CG, Miller CB, Radtke I, et al. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 2008;453(7191):110–114.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Pfeifer H. Management of Philadelphia chromosome- positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc HematolEduc Program. 2009;2009(1):371–381.
   Google Scholar
• Kantarjian H, Thomas D, O’Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004;101(12):2788–2801.
   PubMed Web of Science ®Google Scholar
• Hoelzer D, Thiel E, Loffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988;71(1):123–131.
   PubMed Web of Science ®Google Scholar
• Rowe JM, Buck G, Burnett AK, et al; for Eastern Cooperative Oncology Group; Medical Research Council/National Cancer Research Institute Adult Leukemia Working Party. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106(12):3760–3767.
   PubMed Web of Science ®Google Scholar
• Lazarus HM, Richards SM, Chopra R, et al; for Medical Research Council/National Cancer Research Institute Adult Leukaemia Working Party of the United Kingdom and the Eastern Cooperative Oncology Group. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006;108(2):465–472.
   PubMed Web of Science ®Google Scholar
• Le QH, Thomas X, Echochard R, et al. Initial and late prognostic factors to predict survival in adult acute lymphoblastic leukaemia. Eur J Haematol. 2006;77(6):471–479.
   Web of Science ®Google Scholar
• Bruggemann M, Raff T, Flohr T, et al; for German Multicenter Study Group for Adult Acute Lymphoblastic Leukemia. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107(3):1116–1123.
   PubMed Web of Science ®Google Scholar
• Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22(20):4075–4086.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Altman A, Pui CH, Younes A, Cairo MS. Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence- based review. J Clin Oncol. 2008;26(16):2767–2778.
   PubMed Web of Science ®Google Scholar
• Mato AR, Riccio BE, Qin L, et al. A predictive model for the detection of tumor lysis syndrome during AML induction therapy. Leuk Lymphoma. 2006;47(5):877–883.
   PubMed Web of Science ®Google Scholar
• Tiu RV Mountantonakis SE, Dunbar AJ, Schreiber MJ Jr. Tumor lysis syndrome. Semin Thromb Hemost. 2007;33(4):397–407.
   Web of Science ®Google Scholar
• Franchini M, DiMinno MN, Coppola A. Disseminated intravascular coagulation in hematologic malignancies. Semin Thromb Hemost. 2010;36(4):388–403.
   PubMed Web of Science ®Google Scholar
• Barbui T, Falanga A. Hemorrhage and thrombosis in acute leukemia. Haematologica Reports. 2005;1(9):48–51.
   Google Scholar
• Sarris A, Cortes J, Kantarjian H, et al. Disseminated intravascular coagulation in adult acute lymphoblastic leukemia: frequent complications with fibrinogen levels less than 100 mg/dL. Leuk Lymphoma. 1996;21(1–2):85–92.
   PubMed Web of Science ®Google Scholar
• Dixit A, Chatterjee T, Mishra P, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb Hemost. 2007;13(3):292–298.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Toyama D, Hirota Y, et al. Disseminated intravas- cular coagulation complicating acute lymphoblastic leukemia: a study of childhood and adult cases. Leuk Lymphoma. 2005;46(8):1169–1176.
   PubMed Web of Science ®Google Scholar
• Higuchi T, Mori H, Niikura H, Omine M, Okada S, Terada H. Disseminated intravascular coagulation in acute lymphoblastic leukemia at presentation and in early phase of remission induction therapy. Ann Hematol. 1998;76(6):263–269.
   Web of Science ®Google Scholar
• Porcu P, Cripe LD, Ng EW, et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma. 2000;39(1–2):1–18.
   PubMed Web of Science ®Google Scholar
• Finazzi G. Prophylactic platelet transfusion in acute leukemia: which threshold should be used. Haematologica. 1998;83(11):961–962.
   Web of Science ®Google Scholar
• Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006;2006(1):133–141.
   Google Scholar
• Gottlieb AJ, Weinberg V, Ellison RR, et al. Efficacy of daunorubicin in the therapy of adult acute lymphocytic leukemia: a prospective randomized trial by cancer and leukemia group B. Blood. 1984;64(1):267–274.
   Web of Science ®Google Scholar
• Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025–2037.
   PubMed Web of Science ®Google Scholar
• Kantarjian HM, Walters RS, Keating MJ, et al. Results of the vincristine, doxorubicin, and dexamethasone regimen in adults with standard- and high-risk acute lymphocytic leukemia. J Clin Oncol. 1990;8(6):994–1004.
   Web of Science ®Google Scholar
• Weiss M, Maslak P, Feldman E, et al. Cytarabine with high-dose mitox- antrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone. J Clin Oncol. 1996;14(9):2480–2485.
   Web of Science ®Google Scholar
• Linker CA, Levitt LJ, O’Donnell M, et al. Improved results of treatment of adult acute lymphoblastic leukemia. Blood. 1987;69(4):1242–1248.
   PubMed Web of Science ®Google Scholar
• Lange BJ, Bostrom BC, Cherlow JM, et al; for Children’s Cancer Group. Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children’s Cancer Group. Blood. 2002;99(3):825–833.
   Web of Science ®Google Scholar
• Riehm H, Gadner H, Henze G et al Acute lymphoblastic leukemia: treatment results in three BFM studes (1970–1981) In: Murphy SB, Gilbert JR, eds. Leukemia Research: Advances in Cell Biology and Treatment. New York: Elsevier Science Publishing; 1983:321–263.
   Google Scholar
• Rijneveld AW, van der Holt B, Daenen SM, et al; for Dutch-Belgian HOVON Cooperative Group. Intensified chemotherapy inspired by a pediatric regimen combined with allogeneic transplantation in adult patients with acute lymphoblastic leukemia up to the age of 40. Leukemia. 2011;25(11):1697–1703.
   PubMed Web of Science ®Google Scholar
• Annino L, Vegna ML, Camera A et al for the GIMEMA group Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study Blood. 2002;99(3):863–871.
   Google Scholar
• Ottmann OG, Pfeifer H. First-line treatment of Philadelphia chromosome-positive acute lymphoblastic leukaemia in adults. Curr Opin Oncol. 2009;21 Suppl 1:S43–S46.
   Google Scholar
• Gükbuget N, Wassmann B New approaches to the treatment of adult acute lymphoblastic leukemia Magazine of European Medical Oncology 2009;2:280–288.
   Google Scholar
• Gleissner B, Gokbuget N, Bartram CR, et al; for German Multicenter Trials of Adult Acute Lymphoblastic Leukemia Study Group. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: a prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99(5):1536–1543.
   PubMed Web of Science ®Google Scholar
• Yanada M, Ohno R, Naoe T. Recent advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol. 2009;89(1):3–13.
   Web of Science ®Google Scholar
• Dombret H, Gabert J, Boiron JM, et al; for Groupe d’Etude et de Traitement de la Leucémie Aiguë Lymphoblastique de l’Adulte (GET-LALA Group). Outcome of treatment in adults with Philadelphia chromosome- positive acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 trial. Blood. 2002;100(7):2357–2366.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome- positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the international ALL trial MRC UKALLXII/ECOG2993. Blood. 2009;113(19):4489–4496.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Gokbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108(5):1469–1477.
   PubMed Web of Science ®Google Scholar
• De Labarthe A, Rousselot P, Huguet-Rigal F, et al; for Group for Research on Adult Acute Lymphoblastic Leukemia. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study. Blood. 2007;109(4):1408–1413.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Wassmann B, Pfeifer H, et al; for German Multicenter Study Group for Adult ALL. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL). Cancer. 2007;109(10):2068–2076.
   PubMed Web of Science ®Google Scholar
• Gruber F, Mustjoki S, Porkka K. Impact of tyrosine kinase inhibitors on patient outcomes in Philadelphia chromosome-positive acute lymphoblastic leukaemia. British Journal of Haematology. 2009;145:581–597.
   PubMed Web of Science ®Google Scholar
• Vignetti M, Fazi P, Cimino G, et al. Imatinib plus steroids induces complete remissions and prolonged survival in elderly Philadelpha chromosome-positive patients with acute lymphoblastic leukemia without additional chemotherapy: results of the Gruppo Italiano Malattie Ematologiche dell’Adulto (GIMEMA) LAL0201-B protocol. Blood. 2007;109(9):3676–3678.
   PubMed Web of Science ®Google Scholar
• Wassmann B, Pfeifer H, Stadler M, et al. Early molecular response to posttransplantation imatinib determines outcome in MRD+ Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2005;106(2):458–463.
   PubMed Web of Science ®Google Scholar
• O’Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65(11):4500–4505.
   PubMed Web of Science ®Google Scholar
• Dai H, Marbach P, Lemaire M, Hayes M, Elmquist WF. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J Pharmacol Exp Ther. 2003;304(3):1085–1092.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007;110(7):2309–2315.
   PubMed Web of Science ®Google Scholar
• Foà R, Vitale A, Vignetti M, et al; for GIMEMA Acute Leukemia Working Party. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118(25):6521–6528.
   PubMed Web of Science ®Google Scholar
• Kim DY, Joo YD, Lee JH, et al. Nilotinib combined with multi-agent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: interim results of Korean Adult ALL Working Party phase 2 study [abstract]. Blood. 2011;118(21):1517.
   Web of Science ®Google Scholar
• Cortes JE, Kim DW, Pinilla-Ibarz J, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation [abstract]. Blood. 2011;118(21):109.
   Web of Science ®Google Scholar
• Vey N, Thomas X, Picard C, et al; for GET-LALA Group the Swiss Group for Clinical Cancer Research (SAKK). Allogeneic stem cell transplantation improves the outcome of adults with t(1;19)/E2 A-PBX1 and t(4;11)/MLL-AF4 positive B-cell acute lymphoblastic leukemia: results of the prospective multicenter LALA-94 study. Leukemia. 2006;20(12):2155–2161.
   PubMed Web of Science ®Google Scholar
• Yanada M, Matsuo K, Suzuki T, Naoe T. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high-risk acute lymphoblastic leukemia: a metaanalysis. Cancer. 2006;106(12):2657–2663.
   PubMed Web of Science ®Google Scholar
• Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standardrisk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111(4):1827–1833.
   PubMed Web of Science ®Google Scholar
• Nishiwaki S, Inamoto Y, Imamura M, et al. Reduced-intensity versus conventional myeloablative conditioning for patients with Philadelphia chromosome-negative acute lymphoblastic leukemia in complete remission. Blood. 2011;117(13):3698–3699.
   PubMed Web of Science ®Google Scholar
• Ram R, Storb R, Sandmaier BM, et al. Non-myeloablative conditioning with allogeneic hematopoietic cell transplantation for the treatment of high-risk acute lymphoblastic leukemia. Haematologica 2011;96(8):1113–1120.
   PubMed Web of Science ®Google Scholar
• Fielding AK, Buck G, Lazarus H, et al. Imatinib significantly enhances long-term outcomes in Philadelphia-positive acute lymphoblastic leukaemia: final results of the UKALLXII/ECOG2993 Trial [abstract]. Blood. 2010;116:493.
   Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science. 2008;321(5891):974–977.
   PubMed Web of Science ®Google Scholar
• Topp MS, Kufer P, Gükbuget N, et al. Targeted therapy with the T-cell- engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol. 2011;29(18):2493–2498.
   PubMed Web of Science ®Google Scholar
• Thomas DA, O’Brien S, Jorgensen JL, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113(25):6330–6337.
   PubMed Web of Science ®Google Scholar
• Hoelzer DH, Huettmann AM, Kaul FK, et al. Immunochemotherapy with rituximab in adult CD20+ B-precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as high risk (HR) patients with SCT [abstract]. Haematologica. 2009;94 Suppl 2:481.
   Google Scholar
• Hoelzer D, Gükbuget N, Beck J, et al. Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2004;104 Suppl 1:2732.
   Google Scholar
• Thomas DA, O’Brien S, Faderl S, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia. J Clin Oncol. 2010;28(24):3880–3889.
   PubMed Web of Science ®Google Scholar
• Stock W, Sanford B, Lozanski G, et al. Alemtuzumab can be incorporated into front-line therapy of adult acute lymphoblastic leukemia (ALL): final phase I results of a Cancer and Leukemia Group B Study (CALGB 10102) [abstract]. Blood. 2009;114:838.
   Web of Science ®Google Scholar
• Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med. 2002;8(4 Suppl):S43–S48.
   Web of Science ®Google Scholar
• Batova A, Shao LE, Diccianni MB, et al. The histone deacetylase inhibitor AN-9 has selective toxicity to acute leukemia and drug- resistant primary leukemia and cancer cell lines. Blood. 2002;100(9):3319–3324.
   Web of Science ®Google Scholar
• Sakajiri S, Kumagai T, Kawamata N, Saitoh T, Said JW, Koeffler HP Histone deacetylase inhibitors profoundly decrease proliferation of human lymphoid cancer cell lines. ExpHematol. 2005;33(1):53–61.
   Web of Science ®Google Scholar
• Bueso-Ramos C, Xu YL, McDonnell TJ, et al. Protein expression of a triad of frequently methylated genes, p73, p57 Kip2, and p15, has prognostic value in adult acute lymphocytic leukemia independently of its methylation status. J Clin Oncol. 2005;23(17):3932–3939.
   Web of Science ®Google Scholar
• Vezina C, Kudelski A, Sehgal SN. Rapamycin (AY-22,989) a new antifungal antibiotic: I. Taxonomy of the producing streptomycete and isolation of the active principle. J Antibiot (Tokyo). 1975;28(10):721–726.
   PubMed Web of Science ®Google Scholar
• Douros J, Suffness M. New antitumor substances of natural origin. Cancer Treat Rev. 1981;8(1):63–87.
   PubMed Web of Science ®Google Scholar
• Dilling MB, Dias P, Shapiro DN, Germain GS, Johnson RK, Houghton PJ. Rapamycin selectively inhibits the growth of childhood rhabdomyosarcoma cells through inhibition of signaling via the type I insulin-like growth factor receptor. Cancer Res. 1994;54(4):903–907.
   Web of Science ®Google Scholar
• Majewski M, Korecka M, Kossev P, et al. The immunosuppresive mac- rolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc Natl Acad Sci U S A. 2000;97(8):4285–4290.
   PubMed Web of Science ®Google Scholar
• Brown VI, Fang JJ, Alcorn K, et al. Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by Il-7-mediated signaling. Proc Natl Acad Sci U S A. 2003;100(25):15113–15118.
   PubMed Web of Science ®Google Scholar
• Teachey DT, Obzut DA, Cooperman J, et al. The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL. Blood. 2006;107(3):1149–1155.
   Web of Science ®Google Scholar
• Teachey DT, Sheen C, Hall J, et al. mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia. Blood. 2008;112(5):2020–2023.
   PubMed Web of Science ®Google Scholar
• Carow CE, Levenstein M, Kauffman SH, et al. Expression of the hematopoietic growth factor receptor FLT3 (STK-1/Flk2) in human leukemias. Blood. 1996;87(3):1089–1096.
   PubMed Web of Science ®Google Scholar
• Armstrong SA, Kung AL, Mabon ME, et al. Inhibition of FLT3 in MLL: validation of a therapeutic target identified by gene expression based classification. Cancer Cell. 2003;3(2):173–183.
   PubMed Web of Science ®Google Scholar
• Torelli GF, Guarini A, Porzia A, et al. FLT3 inhibition in t(4;11)+ adult acute lymphoid leukaemia. Br J Haematol. 2005;130(1):43–50.
   Web of Science ®Google Scholar
• Levis M, Pham R, Smith BD, Small D. In vitro studies of a FLT3 inhibitor combined with chemotherapy: sequence of administration is important to achieve synergistic cytotoxic effects. Blood. 2004;104(4):1145–1150.
   PubMed Web of Science ®Google Scholar
• Dasmahapatra G, Almenara JA, Grant S. Flavopiridol and histone deacetylase inhibitors promote mitochondrial injury and cell death in human leukemia cells that overexpress Bcl-2. Mol Pharmacol. 2006;69(1):288–298.
   PubMed Web of Science ®Google Scholar
• Karp JE, Passaniti A, Gojo I, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res. 2005;11(23):8403–8412.
   PubMed Web of Science ®Google Scholar
• Blum W, Phelps MA, Klisovic RB, et al. Phase I clinical and pharmacokinetic study of a novel schedule of flavopiridol in relapsed or refractory acute leukemias. Haematologica. 2010;95(7):1098–1105.
   PubMed Web of Science ®Google Scholar
• Armstrong F, Brunet de la Grange P, Gerby B, et al. NOTCH is a key regulator of human T-cell acute leukemia initiating cell activity. Blood. 2009;113(8):1730–1740.
   Web of Science ®Google Scholar
• Deangelo DJ, Stone RM, Silverman LB, et al. A phase I clinical trial of the NOTCH inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias [abstract]. J Clin Oncol. 2006;24(18 Suppl):357.
   Web of Science ®Google Scholar
• Ponomaryov T, Peled A, Petit I, et al. Induction of chemokine stromal- derived factor-1 following DNA damage improves human stem cell function. J Clin Invest. 2000;106(11):1331–1339.
   PubMed Web of Science ®Google Scholar
• Juarez J, Dela Pena A, Baraz R, et al. CXCR4 antagonists mobilize childhood acute lymphoblastic leukemia cells into the peripheral blood and inhibit engraftment. Leukemia. 2007;21(6):1249–1257.
   PubMed Web of Science ®Google Scholar
• King RW, Deshaies RJ, Peters JM, Kirschner MW. How proteolysis drives the cell cycle. Science. 1996;274(5293):1652–1659.
   PubMed Web of Science ®Google Scholar
• Horton TM, Gannavarapu A, Blaney SM, D’Argenio DZ, Plon SE, Berg SL. Bortezomib interactions with chemotherapy agents in acute leukemia in vitro. Cancer Chemother Pharmacol. 2006;58(1):13–23.
   PubMed Web of Science ®Google Scholar
• Messinger Y, Gaynon P, Raetz E, et al. Phase I study of bortezomib combined with chemotherapy in children with relapsed childhood acute lymphoblastic leukemia (ALL): a report from the Therapeutic Advances in Childhood Leukemia (TACL) Consortium. Pediatr Blood Cancer. 2010;55(2):254–259.
   PubMed Web of Science ®Google Scholar
• Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038–1042.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome- positive acute lymphoid leukemias. Blood. 2002;100:1965–1971.
   PubMed Web of Science ®Google Scholar
• Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinib-resis- tant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531.
   PubMed Web of Science ®Google Scholar
• Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase II study. Blood. 2007;110:2309–2315.
   PubMed Web of Science ®Google Scholar
• Porkka K, Martinelli G, Ottmann OG, et al. Dasatinib efficacy in patients with imatinib-resistant/intolerant Philadelphia chromosome- positive acute lymphoblastic leukemia: 24-month data from START-L Haematologica. 2008, 93:(s1):1 (abstract 0001).
   Google Scholar
• Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542–2551.
   PubMed Web of Science ®Google Scholar
• Ottmann OG, Larson RA, Kantarjian HM, et al. Nilotinib in patients with relapsed/refractory Philadelphia chromosome-positive actue lymphoblastic leukemia who are resistant or intolerant to imatinib Blood (ASH Annual Meeting Abstracts) 2007;110:2815.
   Google Scholar
• Gambacorti-Passerini C, Cortes J, Kantarjian H, et al. Bosutinib (SKI-606) shows high tolerability and clinical activity in patients with Philadelphia chromosome-positive leukemias. Haematologica. 2008;93(s1):160–161 (abstract 0403).
   Google Scholar